NIPT or NIPS (non-invasive prenatal screening) looks at fragments of DNA (cell-free DNA or cfDNA) in your blood during pregnancy to provide accurate information about the likelihood of chromosomal conditions that can impact your baby’s health. NIPT can be performed as early as 10 weeks of pregnancy and screens for the most common chromosomal conditions such as trisomy 21 (Down syndrome), trisomy 18, trisomy 13, sex chromosome aneuploidies (SCA) and 22q11.2 microdeletion. Some NIPTs such as the Harmony prenatal test also provide the option of reporting the sex of your baby.
Previously, NIPT was offered only to women with pregnancies at high risk for chromosomal conditions, such as women over 35 or with a family history of chromosomal conditions. However, professional societies such as The American College of Medical Genetics and Genomics (ACMG) now recommend that doctors inform all pregnant women regardless of age or risk about the fact that cfDNA-based NIPT is the most sensitive screening option for trisomy 21, trisomy 18 and trisomy 13.1 The International Society for Prenatal Diagnosis (ISPD) considers NIPT as appropriate to be offered to all pregnant women as a primary screening test.2
NIPT is performed with a simple blood draw from the mother, so it is considered very safe.
cfDNA-based NIPT is recognized as the most sensitive screening option for trisomy 21 (Down syndrome), trisomy 18, and trisomy 13.1 The Harmony prenatal test has been shown to have superior accuracy in a direct comparison to traditional first trimester screening in over 15,000 women.3 However, not all NIPTs perform with the same accuracy. NIPT for very rare conditions, such as those offered in microdeletion panels, have unclear accuracy.
NIPT is a blood test that provides you an opportunity to obtain accurate information about the likelihood for the most common chromosomal conditions. It can be performed as early as 10 weeks of pregnancy without posing a risk to the baby. Because NIPT is a prenatal screening test it cannot rule out the possibility of chromosomal conditions. In the case of a high probability result, your care provider may offer follow up testing to confirm a diagnosis.
Prenatal diagnostic tests such as amniocentesis or chorionic villus sampling (CVS) require collection of the baby’s cells in the amniotic fluid or the placenta with a needle and are therefore considered invasive. Diagnostic tests provide a definitive answer; however, they pose a slight chance of loss of pregnancy due to the procedure itself.4
Talk to your healthcare provider about your prenatal testing options. Some NIPTs such as the Harmony test are available to women of any age, in singleton, twin and egg donor pregnancies. Your doctor will be able to order the test for you.
The Harmony prenatal test is a non-invasive prenatal test (NIPT) based on cell-free DNA analysis and is considered a prenatal screening test, not a diagnostic test. The Harmony test does not screen for potential chromosomal or genetic conditions other than those expressly identified here. All women should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate. The Harmony prenatal test was developed, and its performance characteristics determined by Ariosa Diagnostics, Inc., a CLIA-certified and CAP-accredited clinical laboratory in San Jose, CA USA. This testing service has not been cleared or approved by the US FDA.
HARMONY is a trademark of Roche. All other product names and trademarks are the property of their respective owners.